Trial reportInternational journal of medical sciences2021
Radiomics based on fluoro-deoxyglucose positron emission tomography predicts liver fibrosis in biopsy-proven MAFLD: a pilot study.
Trial report in International journal of medical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.
- Application of machine learning and deep learning in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis.Journal of advanced research · 2026Pooled it
- Role of radiomics in staging liver fibrosis: a meta-analysis.BMC medical imaging · 2024Pooled it
- Illuminating Glucose: How to Unveil Organ-Specific Insulin Resistance and Guide Metabolic Strategies in Diabetes.Diabetes/metabolism research and reviews · 2026Review
- Research Progress on the Application of Radiomics and Deep Learning in Liver Fibrosis.Journal of imaging · 2026Review
- Identification of Key Genes Related to Both Lipid Metabolism Disorders and Inflammation in MAFLD.Biomedicines · 2025Article
- Mild-moderate alcohol consumption and diabetes are associated with liver fibrosis in patients with biopsy-proven MASLD.Frontiers in pharmacology · 2024Article
- Article
- An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease.Hepatobiliary surgery and nutrition · 2023Review
- Evaluation of [Molecular imaging and biology · 2022Article
- Clinical and radiomic factors for predicting invasiveness in pulmonary ground‑glass opacity.Experimental and therapeutic medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.